Merck & Co., Inc. and Evotec SE: A Comprehensive Revenue Analysis

Merck vs. Evotec: A Decade of Revenue Dynamics

__timestamp	Evotec SE	Merck & Co., Inc.
Wednesday, January 1, 2014	89496000	42237000000
Thursday, January 1, 2015	127677000	39498000000
Friday, January 1, 2016	164507000	39807000000
Sunday, January 1, 2017	257630000	40122000000
Monday, January 1, 2018	375405000	42294000000
Tuesday, January 1, 2019	446437000	46840000000
Wednesday, January 1, 2020	500924000	41518000000
Friday, January 1, 2021	618034000	48704000000
Saturday, January 1, 2022	751448000	59283000000
Sunday, January 1, 2023	781426000	60115000000

In pursuit of knowledge

A Tale of Two Giants: Merck & Co., Inc. vs. Evotec SE

In the ever-evolving pharmaceutical landscape, Merck & Co., Inc. and Evotec SE stand as titans, each carving a unique path. Over the past decade, Merck's revenue has consistently dwarfed that of Evotec, with 2023 figures showing Merck's revenue at approximately 60 billion USD, a staggering 77 times more than Evotec's 781 million USD. However, Evotec's growth trajectory is noteworthy, with a nearly 800% increase in revenue since 2014, compared to Merck's 42% growth. This contrast highlights the dynamic nature of the industry, where established giants and agile innovators coexist. As we look to the future, the question remains: will Evotec's rapid growth continue to close the gap, or will Merck's dominance persist? This analysis offers a glimpse into the strategic maneuvers of these pharmaceutical powerhouses.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025